<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100240</url>
  </required_header>
  <id_info>
    <org_study_id>81501328</org_study_id>
    <nct_id>NCT03100240</nct_id>
  </id_info>
  <brief_title>The Mechanism of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and IR</brief_title>
  <official_title>The Preliminary Mechanism Study of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      NF-κB pathway activation-induced endometrial insulin resistance was one of the causes of&#xD;
      infertility patients with PCOS and insulin resistance whose endometrial receptivity is&#xD;
      declined .The investigators' previous findings indicated that the use of modified utral-long&#xD;
      protocols ( GnRH-a was used twice in mid-luteal phaes) can improve clinical outcomes by&#xD;
      improving endometrial receptivity in patients with PCOS , but the mechanism was not clear.&#xD;
      Previous research also found that GnRH-a reduced the activity of NF-κB pathway in endometrial&#xD;
      stromal cells and depended the dose and time.Thus, The investigators' subject will try to&#xD;
      applicate GnRH-a to explore the influence of NF-κB pathway activity 、the state of insulin&#xD;
      resistance and embryo implantation rate ;then we will investgate GnRH-a whether reduce NF-κB&#xD;
      pathway activity-induced insulin resistance and ultimately improve endometrial receptivity by&#xD;
      using GnRH-a in infertility patients with PCOS and insulin resistance.The investigators'&#xD;
      research attempt to provide ideas for seeking inflammatory medication target in assisted&#xD;
      reproductive technology in patients with PCOS by exploring the immune mechanism of GnRHa on&#xD;
      improving the endometrial receptivity .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The endometrial biopsy was performed in the previous cycle of the protocol. According to the&#xD;
      expression of NF-κB in the endometrium random group. The difference of NF - κB expression in&#xD;
      patients with different protocol were compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It is difficult to recruit patients.&#xD;
  </why_stopped>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>28 days after transplantation</time_frame>
    <description>a beating heart tube was 99 detected by ultrasound examination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified Supper Long Protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>long protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified Supper Long Protocol</intervention_name>
    <description>In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&lt;36years,&#xD;
&#xD;
          -  PCOS,&#xD;
&#xD;
          -  Insulin resistance (HOMA-IR = fasting insulin (FINS) × fasting blood glucose (FPG) /&#xD;
             22.5, HOMA-IR ≥ 2.69 ）;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus and&#xD;
             uterine mediastinum),&#xD;
&#xD;
          -  intrauterine adhesions,&#xD;
&#xD;
          -  endometriosis, adenomyosis,&#xD;
&#xD;
          -  Hydrosalpinx,&#xD;
&#xD;
          -  uterine fibroids (submucosal fibroids, non-mucosal fibroids &gt; 4 cm and / or&#xD;
             endometrial pressure),&#xD;
&#xD;
          -  Hyroid dysfunction and hyperprolactinemia.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of CITIC-XIANGYA</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

